Latest News

Roche in take-over deal with GenMark Diagnostics

© Roche AG


by tg

Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.

The US$1.8bn cash merger – US$ 24.05 per share –  is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s unaffected closing share price on February 10, 2021.

GenMark’s multiplex PCR panel testing portfolio will complement Roche’s current molecular diagnostics portfolio. According to Thomas Schinecker, CEO Roche Diagnostics, GenMarl’s panel testing "provides faster targeted therapeutic intervention, resulting in improved patient outcomes and reduced hospital stays."

Utilizing GenMark’s point-of-care eSensor detection technology, GenMark’s eSensor XT-8 and ePlex systems are designed to address a broad range of infectious disease testing needs, including respiratory, bloodstream and gastrointestinal infections.

Novartis inks US-$1.3bn deal with Dunad Therapeutics

British start-up company Dunad Therapeutics has signed a collaboration and license agreement with Novartis AG to generate orally bioavailable...

BioNTech SE licences Cresendo Bio’s Humabody technology

The three-year collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise including mRNA-based antibodies and cell therapies...

Evotec and Boehringer Ingelheim enter drug discovery deal

The companies did not disclose any financial details about their partnership in drug discovery and target validation. Evotec's mission within the...

EU orders up Valneva’s inactivated Covid-19 vaccine

The European Commission has approved an agreement with Valneva under which the French vaccine maker would supply up to 60 million doses of VLA2001,...

EC signs prepurchase agreement with Valneva

It’s the 8th contract of the European Commission with a COVID-19 vaccine producer. Under the now signed agreement, Austrian-French (Lyon/Vienna)...

From make-up to jet fuel: Breakthrough for Global Bioenergies

What does eye shadow have to do with biojet fuel? A lot, if you ask Global Bioenergies, a Evry-based biotech that is known for having developed a...

Stock market boom: Two biotechs go public

After Evotec’s IPO, two more European companies have gone public: IO Biotech raised US$100m in its IPO on Nasdaq Global Market, selling 7.15 million...